Protalix BioTherapeutics, Inc.
PLXAMEXHealthcare● Active
$1.96
$-0.03(-1.51%)
Market Cap$157920418
P/E Ratio—
52W High$3.19
52W Low$1.32
Protalix BioTherapeutics, Inc. (PLX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PLX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $52.74M | $53.40M | $65.49M | $47.64M | $38.35M |
| Cost of Revenue | $27.51M | $24.32M | $22.98M | $19.59M | $16.35M |
| Gross Profit | $25.24M | $29.08M | $42.51M | $28.05M | $22.00M |
| Gross Margin %(computed) | 47.85% | 54.46% | 64.91% | 58.87% | 57.37% |
| Operating Expenses | |||||
| R&D Expenses | $19.05M | $12.97M | $17.09M | $29.35M | $29.73M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | ($13.58M) | ($4.02M) |
| Total Operating Expenses | $30.74M | $25.16M | $32.05M | $41.06M | $42.46M |
| Operating Income | ($5.50M) | $3.92M | $10.46M | ($13.01M) | ($20.46M) |
| Operating Margin %(computed) | -10.43% | 7.34% | 15.97% | -27.32% | -53.36% |
| Interest Income | $1.08M | $1.30M | $1.29M | $1.15M | $0.40M |
| Interest Expense | $1.19M | $1.06M | $3.18M | $2.53M | $7.52M |
| Income Before Tax | ($5.61M) | $4.15M | $8.57M | ($14.40M) | ($27.58M) |
| Income Tax Expense | $1.00M | $1.22M | $0.25M | $0.53M | $0.00M |
| Net Income | ($6.60M) | $2.93M | $8.31M | ($14.93M) | ($27.58M) |
| Net Margin %(computed) | -12.52% | 5.49% | 12.69% | -31.33% | -71.92% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.08 | $0.04 | $0.12 | $-0.31 | $-0.62 |
| Wtd Avg Shares | 78.55M | 72.53M | 67.51M | 48.47M | 44.14M |
| EBITDA | ($4.04M) | $6.52M | $12.94M | ($10.78M) | ($18.94M) |
| EBITDA Margin %(computed) | -7.65% | 12.21% | 19.75% | -22.63% | -49.40% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Protalix BioTherapeutics, Inc. data
About Protalix BioTherapeutics, Inc. (PLX) Income Statement
Protalix BioTherapeutics, Inc. (PLX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PLX reported revenue of $0.05B, gross profit of $0.03B (gross margin 47.85%), and net income of ($0.01B) — a net profit margin of -12.52%.
Frequently asked questions
PLX · 4 questionsProtalix BioTherapeutics, Inc. (PLX) reported revenue of $0.05B for 2025, down 1.2% year-over-year.
PLX revenuePLX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08